GRI

GRI Bio, Inc. - Common Stock (GRI)

About GRI Bio, Inc. - Common Stock (GRI)

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

Details

Daily high

$1.51

Daily low

$1.41

Price at open

$1.45

52 Week High

$130.39

52 Week Low

$1.10

Market cap

1.1M

Dividend yield

0.00%

Volume

3,901

Avg. volume

950,662

P/E ratio

-.01

GRI Bio, Inc. - Common Stock News